Johnson & Johnson: 138 Years of Pioneering Healthcare
2024-01-15
高管变更
Preview
来源: Healthcare Digital
Credit | Johnson & Johnson
Science and Technology Will Advance Human Health More in the Next Decade Than It Has in the Last Century, Says Joaquin Duato, Johnson & Johnson CEO
Johnson & Johnson was founded in 1886 and is now one of the largest healthcare companies in the world, consistently ranking among the top biotech and pharmaceutical companies based on market capitalisation.
Headquartered in New Jersey, US, but with its over 130,000 employees spanning the world, the company comprises two main businesses: J&J Innovative Medicine, and J&J MedTech, as well as subsidiaries including Band-Aid, Neutrogena, and Tylenol.
Rooted in a belief that health is everything, Johnson & Johnson has developed strength in healthcare innovation to work towards its goal of building a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal.
The past of healthcare looking to the future
Johnson & Johnson is looking toward a future of transformational science, innovative technology and geographic expansion funded by a maintained multi-faceted and disciplined capital allocation strategy. Coming into 2024, the company is looking towards operational sales growth in the range of 5-6%.
“Science and technology will advance human health more in the next decade than it has in the last century, leading to more effective and personalised treatment, earlier intervention, and smarter, less invasive healthcare,” believes Joaquin Duato, Chairman and Chief Executive Officer.
“The breadth of our scientific capabilities, diverse portfolio and robust pipelines uniquely positions Johnson & Johnson to be a leader in this next wave of innovation while delivering strong financial performance.”
Duato has been with Johnson & Johnson for over three decades, serving as Vice Chairman of the Executive Committee before becoming Jonhson & Johnson’s eighth CEO in January 2022 and Chairman in January 2023. Duato is Johnson & Johnson’s first CEO with dual citizenship, which he holds between the US and Spain. He has an MBA from ESADE in Barcelona, Spain, and a Master of International Management from Thunderbird School of Global Management in Phoenix, Arizona. Previously, he has served on the board of UNIXEF USA, as the Chairman of PhRMA and as an Advisory Board Member of Tsinghua University School of Pharmaceutical Sciences.
In his vision for Jonhson & Johnson, he isn’t just looking to the next technological developments — he is developing a vision for the company’s long term growth and success.
“We’ve created a clear set of steps to reinvent the business guided by our North Star — saving and improving patient lives,” he says.
“Today, when it comes to the vision for Johnson & Johnson, I’m once again looking 25 years out, steering toward a horizon where we have achieved transformational medical innovations.”
**************
Make sure you check out the latest industry news and insights at Healthcare Digital and also sign up to our global conference series - Tech & AI LIVE 2024
**************
Healthcare Digital is a BizClik brand
*************
Johnson & Johnson was founded in 1886 and is now one of the largest healthcare companies in the world, consistently ranking among the top biotech and pharmaceutical companies based on market capitalisation.
Headquartered in New Jersey, US, but with its over 130,000 employees spanning the world, the company comprises two main businesses: J&J Innovative Medicine, and J&J MedTech, as well as subsidiaries including Band-Aid, Neutrogena, and Tylenol.
Rooted in a belief that health is everything, Johnson & Johnson has developed strength in healthcare innovation to work towards its goal of building a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal.
The past of healthcare looking to the future
Johnson & Johnson is looking toward a future of transformational science, innovative technology and geographic expansion funded by a maintained multi-faceted and disciplined capital allocation strategy. Coming into 2024, the company is looking towards operational sales growth in the range of 5-6%.
“Science and technology will advance human health more in the next decade than it has in the last century, leading to more effective and personalised treatment, earlier intervention, and smarter, less invasive healthcare,” believes Joaquin Duato, Chairman and Chief Executive Officer.
“The breadth of our scientific capabilities, diverse portfolio and robust pipelines uniquely positions Johnson & Johnson to be a leader in this next wave of innovation while delivering strong financial performance.”
Duato has been with Johnson & Johnson for over three decades, serving as Vice Chairman of the Executive Committee before becoming Jonhson & Johnson’s eighth CEO in January 2022 and Chairman in January 2023. Duato is Johnson & Johnson’s first CEO with dual citizenship, which he holds between the US and Spain. He has an MBA from ESADE in Barcelona, Spain, and a Master of International Management from Thunderbird School of Global Management in Phoenix, Arizona. Previously, he has served on the board of UNIXEF USA, as the Chairman of PhRMA and as an Advisory Board Member of Tsinghua University School of Pharmaceutical Sciences.
In his vision for Jonhson & Johnson, he isn’t just looking to the next technological developments — he is developing a vision for the company’s long term growth and success.
“We’ve created a clear set of steps to reinvent the business guided by our North Star — saving and improving patient lives,” he says.
“Today, when it comes to the vision for Johnson & Johnson, I’m once again looking 25 years out, steering toward a horizon where we have achieved transformational medical innovations.”
**************
Make sure you check out the latest industry news and insights at Healthcare Digital and also sign up to our global conference series - Tech & AI LIVE 2024
**************
Healthcare Digital is a BizClik brand
*************
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-药物
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。